Diogo Rau
Known title: SVP & CIDOCIK: 0001860253
Associated companies
Transaction History
| LLY | ▲ Buy | Grant | 4,432 | $4.6M | 2/9/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,674 | $1.7M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,752 | $0 | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Grant | 6,815 | $5.9M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,269 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,466 | $1.2M | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 3,045 | $2.5M | 6/1/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 6,300 | $0 | 6/1/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 6,300 | $0 | 6/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,848 | $1.2M | 6/1/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 7,560 | $0 | 6/1/2022 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 3,166 | $992K | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.